Cite
HARVARD Citation
Dellis, A. et al. (2016). Cost–effectiveness of denosumab as a bone protective agent for patients with castration resistant prostate cancer. Expert review of pharmacoeconomics & outcomes research. pp. 5-10. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Dellis, A. et al. (2016). Cost–effectiveness of denosumab as a bone protective agent for patients with castration resistant prostate cancer. Expert review of pharmacoeconomics & outcomes research. pp. 5-10. [Online].